MASLD

  2. MASLD

COMORBID PATIENT WITH ACTIVE SARS-CoV-2 INFECTION AND METABOLICASSOCIATED STEATOTIC LIVER DISEASE

Pushkarenko O. A., Horlenko O. M., Feysa S. V., Tomey A. I.
2024 Issue 2, 173 adolescents children COVID-19 MASLD metabolic syndrome metabolically associated steatosis of the liver SARS-CoV-2

EPITHELIAL BARRIER DISORDERS AS A COMMON PATHOGENETIC MECHANISM OF CHRONIC BRONCHOPULMONARY DISEASES AND METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE

Pivtorak K. V., Shevchuk T. V.
2026 Issue 1, 180 bronchial asthma COPD epithelial permeability MASLD microbiota

REBUILDING BRIDGES IN THE GUT-LIVER AXIS: MICROBIOME AND BARRIER INTEGRITY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE THERAPY

Kvit K. B., Kharchenko V. V., Bodrevych B. B.
2026 Issue 1, 180 gut microbiome intestinal permeability MASLD microbiome-targeted therapy zonulin